

Spectra Products Inc.

Management Discussion and Analysis

First Quarter Ended March 31, 2023

Spectra Products Inc.

Management Discussion and Analysis

First Quarter Ended March 31, 2023

The following Management Discussion and Analysis (“MD&A”) is supplementary to, and should be read in conjunction with the unaudited interim condensed financial statements for the three months ended March 31, 2023. In this Management Discussion and Analysis all amounts, unless otherwise indicated, are expressed in Canadian dollars. This MD&A is written as of May 24, 2023.

Description of Business

Spectra Products Inc., (“Spectra” or the “Company”), supplies wheel end safety products to the transportation industry in Canada and the United States. The current product line includes Brake Safe, a visual indicator that permits vehicle drivers and maintenance to visually check the brake adjustment condition of a truck, trailer or bus equipped with an air brake system. The Company’s Termin-81[®] product is an extreme pressure lubricant, penetrant and the number one product in the market for protecting Electrical Vehicle charging ports and charging stations which are prone to corrosion. Zafety Lug Lock[®] is a product that prevents wheel-end lug nuts from loosening leading to wheel damage or wheel loss. Hub Alert[®], a heat-sensitive label that is applied to each wheel hub of trucks, trailers, buses and off-road vehicles to provide an early warning of critical temperature threshold levels.

The Company’s products are sold to the transportation industry directly, through traditional transportation distributors and truck/trailer dealerships; and to trailer manufacturers in Canada and the United States.

Financial Instruments and Financial Risk Management

The Company utilizes its risk management strategy to limit its exposure to financial risks resulting from its manufacturing and sales activities and its use of financial instruments including market risk, credit risk and liquidity risk. The Company’s risk management policy has not changed during 2023.

Market Risk

Market risk is the risk that changes in market prices due to external factors such as foreign exchange rates, interest rates, and other factors will affect the value of Spectra’s financial instruments and consequently its income. The objective of market risk management is to mitigate and control exposures to within acceptable parameters.

Foreign currency risk

The Company realizes a portion of its revenue and expenses in foreign currencies. Consequently, some assets, revenue and expenses are exposed to foreign exchange fluctuations. The following assets, revenue and expenses originated in United States dollars and are subject to fluctuations:

As at March 31, 2023

	\$ USD
Net assets	\$ 341,142
Revenue	\$ 265,740
Expenses	\$ 8,237

Foreign currency sensitivity analysis

The Company is exposed to currency risk due to a certain portion of the Company's sales and purchases being in U.S. currency, resulting in U.S. dollar accounts receivable and U.S dollar cash balances. In addition, the company has US dollar denominated investments. These activities result in exposure to fluctuations in foreign currency rates between the U.S. and Canadian dollar. The Company's sensitivity to these foreign currency fluctuations is such that a 10% strengthening or weakening of the U.S. dollar would result in a corresponding \$ 31,218 increase or decrease to the Company's income before taxes and \$ 14,949 to other comprehensive income for the three months ended March 31, 2023.

Interest rate risk

The Company is exposed to interest rate risk due to a Guaranteed Investment Certificate ("GIC") investment. While each investment bears a fixed interest rate for its duration, changes in interest rates would impact the rate of return on future interest-bearing investments. The Company's sensitivity to interest rate fluctuation is such that a 1% change in interest rates would have a corresponding \$1,750 increase or decrease to the Company's income before taxes for the three months ended March 31, 2023.

Credit Risk

Credit risk is the risk that one party to a financial instrument may be unable to discharge their obligation. The Company's main source of credit risk is outstanding accounts receivable and the Company's maximum exposure to credit risk is equal to the carrying value of the financial assets. In order to prevent losses, the Company manages credit risk by assessing the credit worthiness of potential customers and regularly monitoring outstanding accounts receivable. In determining impairment of financial assets, the Company reviews all receivable balances greater than 90 days and assesses customer payment history. At March 31, 2023, three customers accounted for 79% of the Company's total trade receivables (December 31, 2022-three, 79%):

	As at Mar 31, 2023	As at Dec 31, 2022
1-30 days	146,616	243,663
31 - 60 days	76,414	10,831
61 - 90 days	47,089	94,121
90 + days	-	1,550
Total trade receivables	270,119	350,165
Allowance for bad debts	-	-
Net trade receivables	270,119	350,165
Other receivables	24,544	19,350
Total receivables	294,663	369,515

For the three months ended March 31, 2023, one customer accounted for 26% of the Company's revenue (March 31, 2022, three customers, 55% of revenue).

Liquidity Risk

Liquidity risk encompasses the risk that a company cannot meet its financial obligations as they become due. The Company's approach in managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking harm to the Company's reputation. The Company manages its liquidity risk by continuously monitoring its actual cash flows and its forecasted cash flows. In the event the Company's current cash and cash equivalents become insufficient to meet the anticipated need for ongoing expenses, working capital and capital expenditures, the Company will seek additional funds in the form of equity or debt to provide working capital, inventory and capital equipment necessary to implement its business plan.

Fair Value

The Company's financial assets and liabilities are classified and measured as follows:
Cash is classified as financial asset measured at fair value through profit and loss. Accounts receivable and loan receivable are classified as financial assets measured at amortized cost. Investments in equity and subordinated convertible promissory note are classified at fair value through other comprehensive income.

Accounts payable and accrued charges and lease liability are classified as financial liabilities measured at amortized cost. Financial liabilities at amortized cost are recognized initially at fair value plus any directly attributable transaction costs and are subsequently recorded at amortized cost.

The carrying amount of cash, accounts receivable and accounts payable and accrued charges approximates fair value due to the short-term nature of these financial instruments. The carrying amount of loan receivable approximates fair value due to the market interest rate charged. The carrying value of investments in equity and convertible debentures approximate fair value based on quoted prices in active market. The carrying value of the subordinated convertible promissory note is stated at cost because it is an investment in a private corporation. The promissory note is carried at the fair value, being the estimated recoverable amount of the investment, estimated to be \$nil as at March 31, 2023.

Capital Disclosures

The Company's capital structure is comprised of shareholders' equity. There are no restrictions on the Company's capital. In order to maintain and adjust its capital structure, the Company may issue share capital, and issue new debt.

The Company's objectives when managing capital are to ensure operation as a going concern in order to manufacture and sell its products to its customers while providing an adequate return to its shareholders and other stakeholders.

The Company meets its objectives for managing capital through preparation of detailed, annual budgets and the monitoring of financial performance. The Company reviews ongoing cash flow and monitors very closely its receivables and payables. Capital management objectives remain unchanged during 2023.

Financial Results

Selected Financial Information

The accompanying unaudited interim condensed financial statements of the Company and all information in this report have been prepared by management and approved by the Board of Directors of the Company. The interim condensed financial statements were prepared on the basis of International Accounting Standard 34 ("IAS 34") and, where appropriate, reflect management's best estimates and judgments. Management is responsible for the accuracy, integrity and objectivity of the interim condensed financial statements within reasonable limits of materiality. Financial and operating data elsewhere in this report are consistent with the information contained in the interim condensed financial statements.

Non-IFRS Measures

In addition to discussing earnings measures in accordance with IFRS, this MD&A discusses the following non-IFRS measure, which is a performance indicator used by the Company's management and Board of Directors: Earnings before stock-based compensation.

The following table reconciles IFRS measures disclosed in the unaudited interim condensed financial statements for the three months ended March 31, 2022 to Earnings before stock-based compensation:

	Three months ended March 31,	
	2022	2021
Net income (loss) for the period	\$ 80,708	\$ 31,996
Add: stock-based compensation	-	-
Earnings before stock-based compensation	<u>\$ 80,708</u>	<u>\$ 31,996</u>

Internal Controls

To assist management in the discharge of these responsibilities, the Company maintains a system of internal controls designed to provide reasonable assurance that its assets are safeguarded, that only valid and authorized transactions are executed, and that accurate, timely and comprehensive financial information is prepared.

The Board of Directors carries out its responsibility for the interim condensed financial statements in this annual and quarterly report principally through its Audit Committee. A majority of the members of the Audit Committee are independent, non-management directors and all members of the Audit Committee are appointed by the Board of Directors. The Audit Committee meets with management and, where necessary, the external auditors to discuss the results of the annual audit examinations with respect to the adequacy of internal accounting controls and to review and discuss the interim condensed financial statements and financial reporting matters.

SUMMARY OF QUARTERLY RESULTS

The table below sets forth certain information for each of the eight most recent quarters, the most recent quarter being March 31, 2023.

QUARTERLY DATA

Three-month period ending:

Canadian Dollars	3/31/2023	12/31/2022	9/30/2022	6/30/2022	3/31/2022	12/31/2021	9/30/2021	6/30/2021
Revenue	533,572	500,953	461,995	333,976	356,561	390,083	421,848	391,237
Gross Profit	256,471	235,156	247,875	177,896	169,674	199,452	234,858	225,331
SG&A Expenses	129,472	261,893	122,647	107,452	118,301	104,740	103,696	105,767
Income taxes	28,843	19,244	31,055	16,894	11,525	42,152	32,657	29,561
Net income (loss) for the period	80,708	(74,026)	86,414	45,746	31,996	32,093	90,558	82,010
Other comprehensive income (loss)	(47,161)	(56,424)	12,471	(47,308)	813	(29,175)	(36,896)	(99,002)
Total comprehensive income (loss)	33,547	(130,450)	98,885	(1,562)	32,809	2,918	53,662	(16,992)
Earnings before stock-based compensation	80,708	53,974	86,414	45,746	31,996	116,073	90,558	82,010
Income (loss) per share - basic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
- diluted	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Results of Operations

Revenue:

Three months ended March 31, 2023

Revenue for the three months ended March 31, 2023 increased by 50% to \$533,572 compared to revenue of \$356,561 for the three-month period ended March 31, 2022.

Gross Profit

Three months ended March 31, 2023

Gross profit increased by 51% for the three months ended March 31, 2023 to \$256,471 or 48% of revenue from a comparable \$169,674 or 48% percent of revenue for the three months ended March 31, 2022.

Expenses:**Three months ended March 31, 2023**

The Company has elected to present its statement of earnings utilizing a functional basis of classification in accordance with IAS 1. Under the functional classification of presentation, the expenses are classified based on their functions within the Company under specific headings.

Selling costs

Selling costs are comprised of the following categories:

- Commissions
- Travel and courier
- Trade shows

For the quarter ended March 31, 2023, selling costs were \$32,938 , \$7,521 higher than the comparable costs of \$25,417 for the quarter ended March 31, 2022. The increase was due to higher commissions and higher travel costs, partially offset by lower trade show costs.

Administrative costs

Administrative costs are comprised of the following categories:

- Management fees and salaries
- Professional fees
- Insurance
- Premises cost
- Office and general
- Stock based compensation

For the quarter ended March 31, 2023, administrative costs were \$96,534 , \$3,651 higher than the comparable costs of \$92,883 for the quarter ended March 31, 2022. The increase was primarily due to an increase in payroll and office costs.

Finance costs

Finance costs are comprised of interest on long-term debt. Long-term debt is entirely comprised of the lease obligation for the Company's premises.

For the quarter ended March 31, 2023, finance costs were \$2,538 , \$1,205 higher than the comparable costs of \$1,333 for the quarter ended March 31, 2022. The increase is due to a renewal of the Company's premises lease at a higher rate, resulting in increased values for the Company's right of use asset and liability.

Amortization

The Company incurs amortization expense on its right of use asset.

For the three months ended March 31, 2023, amortization expense was \$14,776 , \$8,256 higher than the comparable costs of \$6,520 for the three months ended March 31, 2022. The increase is due to a renewal of the Company's premises lease at a higher rate, resulting in increased values for the Company's right of use asset and liability.

Net income**Three months ended March 31, 2023**

The net income for the three months ended March 31, 2023 was \$80,708 compared to net income of \$31,996 for the three months ended March 31, 2022.

Other Comprehensive Income**Three months ended March 31, 2023**

Other comprehensive loss for the three months ended March 31, 2023 was \$47,161 . This represents unrealized losses on investments net of deferred tax. Other comprehensive loss for the quarter ended March 31, 2022 was \$813 . This represented unrealized losses on investments net of deferred tax.

Total Comprehensive Income
Three months ended March 31, 2023

Total comprehensive loss for the three months ended March 31, 2023 was \$33,547 or \$0.00 per share basic and fully diluted compared to total comprehensive income of \$32,809 or \$0.00 per share basic and fully diluted for the three months ended March 31, 2022.

Investments

As at March 31, 2023, the company had the following investments:

Name	# shares	Value (\$)
Immunoprecise Antibodies	17,647	66,152
Agex Therapeutics	10,000	8,972
Lineage Cell Therapeutics	15,000	30,043
Unity Biotechnology	2,400	5,294
Cross Border Capital (Super Buzz)	10,000	1,300
Far Resources Ltd (Foremost)	100,000	17,000
Miso Brothers - USD \$60,000 Promissory Note)	N/A	-
		<u>128,762</u>

The promissory note is convertible into common shares of the investee upon the fulfilment of certain conditions. The note maturity date was extended from September 20, 2022 to June 30, 2023 and bears interest at 15% payable at maturity. As at March 31, 2023, the Company has not received any accrued interest on this note, and the conditions for conversion have not been met. As a result, the value of this investment has been impaired until such time as it is deemed to be recoverable.

Statement of Financial Position:

Total Assets

Total assets as at March 31, 2023 were \$2,184,812 a decrease of 8% from \$2,383,743 as at March 31, 2022.

Total Liabilities

Total liabilities as at March 31, 2023 were \$406,823 , a decrease of 36% from \$639,301 as at March 31, 2022. The decrease in liabilities is primarily a result of a settling accounts payable balances.

Liquidity and Cash Flow

Three months ended March 31, 2023

During the three months ended March 31, 2023, the operating activities of the Company used \$42,303 in net cash compared to a net cash contribution from operating activities of \$15,946 during the same period in 2022. Investing activities used \$nil of cash during the three months compared to providing \$55,545 during the same period in 2022. Financing activities used \$13,809 of cash during the three months compared to using \$18,212 of cash during the same period in 2022, primarily due to the Normal Course Issuer Bid share buyback program in 2022, described below under Outstanding Share Data.

These resulted in a net decrease in cash resources of \$56,112 and a cash resources balance at the end of the period of \$1,016,955 . During the equivalent period in 2022, the Company showed a net increase in cash resources of \$53,279 and a cash resources balance of \$930,826 at the end of the period.

In addition to the above cash resources, the Company had, at March 31, 2023, investments valued at \$128,762 resulting in short term cash and investments of \$1,145,717 at March 31, 2023, compared to an equivalent amount of \$1,256,193 at December 31, 2022.

Related Party Transactions

During the three months ended March 31, 2023, management fees and salaries totaling \$37,759 were paid to executives who were directors and/or shareholders or to companies controlled by them (2022 - \$27,226).

During the three months the Company accrued USD \$188 of interest from the President on account of the USD \$15,000 loan receivable.

Off Balance Sheet Arrangements

As at March 31, 2023, the Company does not have any material off balance sheet arrangements.

Disclosure Controls and Procedures

The Directors and the President of the Company have evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the first quarter of 2023 and they have concluded that such disclosure controls and procedures are adequate and effective and are subject to regular review and update.

Segmented information

The Company operates in only one business segment and therefore does not report financial results on a segmented basis.

Outstanding Share Data

The Company's authorized share capital consists of an unlimited number of common shares; an unlimited amount of first, second, third and fourth preferred shares and 540,000 second preferred shares, Series 1.

On October 31, 2022, the Company conducted a share consolidation whereby every five pre-consolidation shares were consolidated to one post-consolidation share. Correspondingly, the number of issued and outstanding common shares was reduced by a factor of 5. All historical share amounts have been amended to reflect this consolidation.

As of March 23, 2023, the TSX Venture Exchange accepted the Company's Notice of Intention to make a Normal Course Issuer Bid ("NCIB") to purchase for cancellation up to a maximum of 732,545 common shares of the capital of the Company, from time to time, as the Company considers appropriate. The maximum number of Common Shares to be purchased pursuant to the NCIB represents 5.0% of the Company's 14,650,895 common shares outstanding as at the date above. The NCIB commenced on March 27, 2023 and will terminate on March 26, 2024 or at such earlier time as the NCIB is completed or terminated at the option of the Company.

As at March 31, 2023, there were 14,650,895 outstanding common shares. As at March 31, 2023, the following is a description of the outstanding equity securities and convertible securities previously issued by the Company.

Designation of security	Number outstanding	If convertible, exercisable or exchangeable for common shares, maximum number of common shares issuable
Common shares	14,650,895	14,650,895
Stock options issued as at December 31, 2022	1,400,000	1,400,000

Stock options issued or expired	0	0
Total (maximum number of shares – fully diluted)	16,050,895	16,050,895

Share Options

The Company has a stock option plan that permits the grant of options to directors, officers, employees and consultants. The plan provides for the grant of a maximum number of options equal to ten percent of the issued and outstanding common shares, with a maximum term of five years, fully vesting at the date of grant. The fair value of stock-based compensation is determined using the Black-Scholes option-pricing model. Compensation expense is recognized over the stock option vesting period with a corresponding charge to contributed surplus.

	Options Granted	Weighted Exercise Price
Balance - December 31, 2022	1,400,000	0.16
Granted	0	0.00
Forfeited / Expired	0	0.00
Balance - December 31, 2023	1,400,000	0.16

As at March 31, 2023, there were 1,400,000 outstanding options to acquire common shares (1,400,000 at December 31, 2022).

As at March 31, 2023, there were no outstanding warrants.

Subsequent Event

In connection with the NCIB program as described in above under “Outstanding Share Data”, the Company has purchased 66,000 common shares at a cost of \$11,200 as of the date of this MD&A.

DIVIDEND POLICY

The Company does not currently have a policy of declaring or paying dividends on its common shares and preference shares. The Company intends to retain future earnings for use in its business and does not anticipate paying dividends in the foreseeable future.

OUTLOOK

The Company continues to focus its efforts on expanding the present market for its products while introducing those products into new markets as well as seeking out new products to complement our current wheel end safety offerings.

The Company’s Signature Brake Safe® product is well established in the Canadian market and is gaining sales momentum in the lucrative American market. The Commercial Vehicle Safety Alliance (“CVSA”) is a nonprofit association comprised of local, state, provincial, territorial and federal commercial motor vehicle safety officials and industry representatives. The CVSA holds brake-focused enforcement events throughout the year to identify and remove commercial vehicles with dangerous brake issues from the roadways. Brakes out of adjustment continue to be the number one out-of-service violation in North America as evidenced last year during International Roadcheck and Operation Air Brake.

A program has been developed to educate companies of these enforcement changes and the resulting increased intervention by regulatory agencies in order to capitalize on sales opportunities for Brake Safe.

The Company’s Termin-8R® product is the number one product in the market for protecting Electrical Vehicle charging ports and charging stations. Termin-8R continues to receive strong industry acceptance with a corresponding growth in sales to the transportation segment. The private label arrangement made for a leading supplier to the commercial transport industry is proving to be an excellent performer.

The Company will continue to form strategic distribution alliances in the United States to accelerate its wheel end safety product sales outside the Canadian marketplace.

FORWARD LOOKING STATEMENTS

The preceding MD&A provides a summary of the audited financial information of the Company contained therein. This discussion contains forward-looking statements that involve certain risks and uncertainties, which may include, but are not limited to, statements with respect to the future financial or operating performance of the Company. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others: general business, economic, competitive, political and social uncertainties; the actual results of marketing and sales activities; fluctuations in the value of Canadian dollars relative to other currencies; changes in labor costs or other costs of production including raw materials; delays in financing activities. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.